Cargando…

Pan-cancer analysis and experimental validation of DTL as a potential diagnosis, prognosis and immunotherapy biomarker

BACKGROUND: DTL has been found to be related with multiple cancers. However, comprehensive analyses, which identify the prediction value of DTL in diagnosis, prognosis, immune infiltration and treatment, have rarely been reported so far. METHODS: Combined with the data online databases, the gene exp...

Descripción completa

Detalles Bibliográficos
Autores principales: Tang, Yumei, Lei, Ye, Gao, Peng, Jia, Junting, Du, Huijun, Wang, Qitong, Yan, Zhixin, Zhang, Chen, Liang, Guojun, Wang, Yanfeng, Ma, Weijun, Xing, Nianzeng, Cheng, Le, Ren, Laifeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10088150/
https://www.ncbi.nlm.nih.gov/pubmed/37038185
http://dx.doi.org/10.1186/s12885-023-10755-z
_version_ 1785022508780486656
author Tang, Yumei
Lei, Ye
Gao, Peng
Jia, Junting
Du, Huijun
Wang, Qitong
Yan, Zhixin
Zhang, Chen
Liang, Guojun
Wang, Yanfeng
Ma, Weijun
Xing, Nianzeng
Cheng, Le
Ren, Laifeng
author_facet Tang, Yumei
Lei, Ye
Gao, Peng
Jia, Junting
Du, Huijun
Wang, Qitong
Yan, Zhixin
Zhang, Chen
Liang, Guojun
Wang, Yanfeng
Ma, Weijun
Xing, Nianzeng
Cheng, Le
Ren, Laifeng
author_sort Tang, Yumei
collection PubMed
description BACKGROUND: DTL has been found to be related with multiple cancers. However, comprehensive analyses, which identify the prediction value of DTL in diagnosis, prognosis, immune infiltration and treatment, have rarely been reported so far. METHODS: Combined with the data online databases, the gene expression, gene mutation, function enrichment and the correlations with the immunity status and clinical indexes of DTL were analyzed. Expression of DTL and the degree of immune cell infiltration were examined by immunofluorescence (IF) and immunohistochemistry (IHC) and analyzed by statistical analysis. Furthermore, the influences of DTL on the cell cycle, cell proliferation and apoptosis were detected by live cell imaging, IF and flow cytometric (FC) analysis. Genomic stability assays were conducted by chromosome slide preparation. RESULTS: DTL was widely expressed in various cells and tissues, while it was overexpressed in tumor tissues except acute myeloid leukemia (LAML). Pan-cancer bioinformatics analysis showed that the expression of DTL was correlated with the prognosis, immunotherapy, and clinical indexes in various cancers. In addition, gene set enrichment analysis (GSEA) uncovered that DTL was enriched in oocyte meiosis, pyrimidine metabolism, the cell cycle, the G2M checkpoint, mTORC1 signaling and E2F targets. Furthermore, the overexpression of DTL, and its association with immune cell infiltration and clinical indexes in liver hepatocellular carcinoma (LIHC), bladder urothelial carcinoma (BLCA) and stomach adenocarcinoma (STAD) were verified in our study. It was also verified that overexpression of DTL could regulate the cell cycle, promote cell proliferation and cause genomic instability in cultured cells, which may be the reason why DTL plays a role in the occurrence, progression and treatment of cancer. CONCLUSIONS: Collectively, this study suggested that DTL is of clinical value in the diagnosis, prognosis and treatment of various cancers, and may be a potential biomarker in certain cancers. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12885-023-10755-z.
format Online
Article
Text
id pubmed-10088150
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-100881502023-04-12 Pan-cancer analysis and experimental validation of DTL as a potential diagnosis, prognosis and immunotherapy biomarker Tang, Yumei Lei, Ye Gao, Peng Jia, Junting Du, Huijun Wang, Qitong Yan, Zhixin Zhang, Chen Liang, Guojun Wang, Yanfeng Ma, Weijun Xing, Nianzeng Cheng, Le Ren, Laifeng BMC Cancer Research BACKGROUND: DTL has been found to be related with multiple cancers. However, comprehensive analyses, which identify the prediction value of DTL in diagnosis, prognosis, immune infiltration and treatment, have rarely been reported so far. METHODS: Combined with the data online databases, the gene expression, gene mutation, function enrichment and the correlations with the immunity status and clinical indexes of DTL were analyzed. Expression of DTL and the degree of immune cell infiltration were examined by immunofluorescence (IF) and immunohistochemistry (IHC) and analyzed by statistical analysis. Furthermore, the influences of DTL on the cell cycle, cell proliferation and apoptosis were detected by live cell imaging, IF and flow cytometric (FC) analysis. Genomic stability assays were conducted by chromosome slide preparation. RESULTS: DTL was widely expressed in various cells and tissues, while it was overexpressed in tumor tissues except acute myeloid leukemia (LAML). Pan-cancer bioinformatics analysis showed that the expression of DTL was correlated with the prognosis, immunotherapy, and clinical indexes in various cancers. In addition, gene set enrichment analysis (GSEA) uncovered that DTL was enriched in oocyte meiosis, pyrimidine metabolism, the cell cycle, the G2M checkpoint, mTORC1 signaling and E2F targets. Furthermore, the overexpression of DTL, and its association with immune cell infiltration and clinical indexes in liver hepatocellular carcinoma (LIHC), bladder urothelial carcinoma (BLCA) and stomach adenocarcinoma (STAD) were verified in our study. It was also verified that overexpression of DTL could regulate the cell cycle, promote cell proliferation and cause genomic instability in cultured cells, which may be the reason why DTL plays a role in the occurrence, progression and treatment of cancer. CONCLUSIONS: Collectively, this study suggested that DTL is of clinical value in the diagnosis, prognosis and treatment of various cancers, and may be a potential biomarker in certain cancers. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12885-023-10755-z. BioMed Central 2023-04-10 /pmc/articles/PMC10088150/ /pubmed/37038185 http://dx.doi.org/10.1186/s12885-023-10755-z Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Tang, Yumei
Lei, Ye
Gao, Peng
Jia, Junting
Du, Huijun
Wang, Qitong
Yan, Zhixin
Zhang, Chen
Liang, Guojun
Wang, Yanfeng
Ma, Weijun
Xing, Nianzeng
Cheng, Le
Ren, Laifeng
Pan-cancer analysis and experimental validation of DTL as a potential diagnosis, prognosis and immunotherapy biomarker
title Pan-cancer analysis and experimental validation of DTL as a potential diagnosis, prognosis and immunotherapy biomarker
title_full Pan-cancer analysis and experimental validation of DTL as a potential diagnosis, prognosis and immunotherapy biomarker
title_fullStr Pan-cancer analysis and experimental validation of DTL as a potential diagnosis, prognosis and immunotherapy biomarker
title_full_unstemmed Pan-cancer analysis and experimental validation of DTL as a potential diagnosis, prognosis and immunotherapy biomarker
title_short Pan-cancer analysis and experimental validation of DTL as a potential diagnosis, prognosis and immunotherapy biomarker
title_sort pan-cancer analysis and experimental validation of dtl as a potential diagnosis, prognosis and immunotherapy biomarker
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10088150/
https://www.ncbi.nlm.nih.gov/pubmed/37038185
http://dx.doi.org/10.1186/s12885-023-10755-z
work_keys_str_mv AT tangyumei pancanceranalysisandexperimentalvalidationofdtlasapotentialdiagnosisprognosisandimmunotherapybiomarker
AT leiye pancanceranalysisandexperimentalvalidationofdtlasapotentialdiagnosisprognosisandimmunotherapybiomarker
AT gaopeng pancanceranalysisandexperimentalvalidationofdtlasapotentialdiagnosisprognosisandimmunotherapybiomarker
AT jiajunting pancanceranalysisandexperimentalvalidationofdtlasapotentialdiagnosisprognosisandimmunotherapybiomarker
AT duhuijun pancanceranalysisandexperimentalvalidationofdtlasapotentialdiagnosisprognosisandimmunotherapybiomarker
AT wangqitong pancanceranalysisandexperimentalvalidationofdtlasapotentialdiagnosisprognosisandimmunotherapybiomarker
AT yanzhixin pancanceranalysisandexperimentalvalidationofdtlasapotentialdiagnosisprognosisandimmunotherapybiomarker
AT zhangchen pancanceranalysisandexperimentalvalidationofdtlasapotentialdiagnosisprognosisandimmunotherapybiomarker
AT liangguojun pancanceranalysisandexperimentalvalidationofdtlasapotentialdiagnosisprognosisandimmunotherapybiomarker
AT wangyanfeng pancanceranalysisandexperimentalvalidationofdtlasapotentialdiagnosisprognosisandimmunotherapybiomarker
AT maweijun pancanceranalysisandexperimentalvalidationofdtlasapotentialdiagnosisprognosisandimmunotherapybiomarker
AT xingnianzeng pancanceranalysisandexperimentalvalidationofdtlasapotentialdiagnosisprognosisandimmunotherapybiomarker
AT chengle pancanceranalysisandexperimentalvalidationofdtlasapotentialdiagnosisprognosisandimmunotherapybiomarker
AT renlaifeng pancanceranalysisandexperimentalvalidationofdtlasapotentialdiagnosisprognosisandimmunotherapybiomarker